Skip to main content
SpringerLink
Log in

Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole?

  • original article
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Abstract

Objective

The objective of this study is to evaluate the prognostic value of M30 and M65 levels as markers of apoptotic activity and maternal serum oxidative stress in patients with complete hydatidiform mole (CHM).

Methods

In total, 68 pregnant women were included in the study. The study group included 34 pregnant with CHM, while 34 healthy pregnant were employed as a control group. Venous blood samples were drawn to assess the maternal serum oxidative stress and M30–M65 levels. In addition, a second blood sample was drawn from patients with CHM on day 8 after dilatation evacuation.

Results

Maternal serum oxidative stress and M30–M65 levels were found to be significantly higher in patients with CHM as compared with the control group. It was found that serum β-subunit of human chorionic gonadotropin (β-hCG) level had a significant positive correlation with M30–M65 levels in patients with CHM. In addition, serum M65 level was found to be as effective as β-hCG in the identification of the patients with CHM.

Conclusion

Our results indicated that oxidative stress and apoptosis may play significant roles in CHM development. In addition, it seems that serum M30–M65 levels can presumably be an ancillary laboratory test to β-hCG in the diagnosis and follow-up of the patients with CHM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mak VC, Lee L, Siu MK, et al. Downregulation of ASPP1 in gestational trophoblastic disease: correlation with hypermethylation, apoptotic activity and clinical outcome. Mod Pathol. 2011;24:522–32.

    Article  CAS  PubMed  Google Scholar 

  2. Sebire NJ, Savage PM, Seckl MJ, Fisher RA. Histopathological features of biparental complete hydatidiform moles in women with NLRP7 mutations. Placenta. 2013;34:50–6.

    Article  CAS  PubMed  Google Scholar 

  3. Harma M, Harma M, Kocyigit A, Erel O. Increased DNA damage in patients with complete hydatidiform mole. Mutat Res. 2005;583:49–54.

    Article  CAS  PubMed  Google Scholar 

  4. Buyukhatipoglu H, Kirhan I, Vural M, et al. Oxidative stress increased in healthcare workers working 24-hour on-call shifts. Am J Med Sci. 2010;340:462–7.

    Article  PubMed  Google Scholar 

  5. Aksin M, Incebiyik A, Vural M, et al. Does a risky outcome of antenatal screening test indicate oxidative stress? J Matern Fetal Neonatal Med. 2014;27:1033–7.

    Article  CAS  PubMed  Google Scholar 

  6. Sharp AN, Heazell AE, Crocker IP, Mor G. Placental apoptosis in health and disease. Am J Reprod Immunol. 2010;64:159–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Niknejad H, Khayat-Khoei M, Peirovi H, Abolghasemi H. Human amniotic epithelial cells induce apoptosis of cancer cells: a new anti-tumor therapeutic strategy. Cytotherapy. 2014;16:33–40.

    Article  CAS  PubMed  Google Scholar 

  8. Zhang HJ, Xue WC, Siu MKY, Liao XY, Ngan HYS, Cheung ANY. P63 expression in gestational trophoblastic disease: correlation with proliferation and apoptotic dynamics. Int J Gynecol Pathol. 2009;28:172–8.

    Article  PubMed  Google Scholar 

  9. Ustaalioglu BB, Bilici A, Ercan S, Seker M, Orcun A, Gumus M. The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer. Med Oncol. 2013;30:551.

    Article  PubMed  Google Scholar 

  10. Yildiz I, Sen F, Kilic L, et al. Serum M65 as a biomarker for metastatic renal cell carcinoma. Clin Genitourin Cancer. 2013;11:290–6.

    Article  PubMed  Google Scholar 

  11. Bilici A, Ustaalioglu BBO, Ercan S, et al. The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer. Tumor Biol. 2012;33:2201–8.

    Article  CAS  Google Scholar 

  12. Yildiz I, Tas F, Kilic L, et al. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer. Cancer Chemother Pharmacol. 2013;72:437–44.

    Article  CAS  PubMed  Google Scholar 

  13. Chiu PM, Ngan YS, Khoo US, Cheung AN. Apoptotic activity in gestational trophoblastic disease correlates with clinical outcome: assessment by the caspase-related M30 cytodeath antibody. Histopathology. 2001;38:243–9.

    Article  CAS  PubMed  Google Scholar 

  14. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–91.

    Article  PubMed  Google Scholar 

  15. Camuzcuoglu H, Arioz DT, Toy H, Kurt S, Celik H, Aksoy N. Assessment of preoperative serum prolidase activity in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2009;147:97–100.

    Article  CAS  PubMed  Google Scholar 

  16. Harma M, Harma M. Defective placentation and resultant oxidative stress play a similar role in complete hydatidiform mole to that in preeclampsia and early pregnancy loss. Med Hypotheses. 2006;66:100–2.

    Article  CAS  PubMed  Google Scholar 

  17. Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol. 2005;3:1–28.

    Article  CAS  Google Scholar 

  18. Lanoix D, Lacasse AA, Reiter RJ, Vaillancourt C. Melatonin: the watchdog of villous trophoblast homeostasis against hypoxia/reoxygenation-induced oxidative stress and apoptosis. Mol Cell Endocrinol. 2013;381:35–45.

    Article  CAS  PubMed  Google Scholar 

  19. Tuuli MG, Longtine MS, Nelson DM. Review: oxygen and trophoblast biology—a source of controversy. Placenta. 2011;32:109–18.

    Article  Google Scholar 

  20. Moll SJ, Jones CJP, Crocker IP, Baker PN, Heazell AEP. Epidermal growth factor rescues trophoblast apoptosis induced by reactive oxygen species. Apoptosis. 2007;12:1611–22.

    Article  CAS  PubMed  Google Scholar 

  21. John K, Wielgosz S, Schulze-Osthoff K, Bantel H, Hass R. Increased plasma levels of CK-18 as potential cell death biomarker in patients with HELLP syndrome. Cell Death Dis. 2013;4:886–91.

    Article  Google Scholar 

  22. Bilici A, Ustaalioglu BB, Ercan S, et al. Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer? Cancer Chemother Pharmacol. 2011;68:309–16.

    Article  CAS  PubMed  Google Scholar 

  23. Ustaalioglu BO, Bilici A, Ercan S, et al. Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls. Clin Transl Oncol. 2012;14:356–61.

    Article  PubMed  Google Scholar 

  24. Cummings J, Zhou C, Dive C. Application of the beta-expectation tolerance interval to method validation of the M30 and M65 ELISA cell death biomarker assays. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:887–93.

    Article  CAS  PubMed  Google Scholar 

  25. Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. Int Immunopharmacol. 2009;9:645–8.

    Article  CAS  PubMed  Google Scholar 

  26. Ausch C, Buxhofer-Ausch V, Olszewski U, et al. Circulating cytokeratin 18 fragment M65—a potential marker of malignancy in colorectal cancer patients. J Gastrointest Surg. 2009;13:2020–6.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that there are no actual or potential conflicts of interest in relation to this article.

Author information

Authors and Affiliations

  1. Faculty of Medicine, Department of Gynecology and Obstetrics, Harran University, Yenisehir Campus, 63300, Sanliurfa, Turkey

    Adnan Incebiyik, Hakan Camuzcuoglu, Aysun Camuzcuoglu & Nese Gul Hilali

  2. Faculty of Medicine, Department of Gynecology and Obstetrics, Marmara University, Istanbul, Turkey

    Mehmet Vural

  3. Faculty of Medicine, Department of Biochemistry, Harran University, Sanliurfa, Turkey

    Abdullah Taskin & Nurten Aksoy

Authors
  1. Adnan Incebiyik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehmet Vural
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hakan Camuzcuoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abdullah Taskin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aysun Camuzcuoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nese Gul Hilali
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nurten Aksoy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adnan Incebiyik.

Additional information

The abstract of this article was sent to XXIV European Congress of Perinatal Medicine; June 4th to 7th, 2014, Florence/Italy.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Incebiyik, A., Vural, M., Camuzcuoglu, H. et al. Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole?. Wien Klin Wochenschr 128 (Suppl 8), 566–571 (2016). https://doi.org/10.1007/s00508-015-0735-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-015-0735-5

Keywords

Search

Navigation